70% of ovarian teratomas remain stable over time

70% of ovarian teratomas remain stable over time

A far-reaching retrospective study analysing a sample of over 400 women diagnosed with a benign ovarian teratoma, who underwent follow-up over a period of ten years shows that, in most cases - practically 70% - this type of tumour remains stable over time. For this reason, the authors indicate that ongoing ultrasound surveillance can constitute a favourable option to monitor any changes, since the risk of the tumour increasing in size, becoming malignant or causing other complications is very low.

The paper published by the Diagnostic Gynaecological Imaging (DGI) Department of Dexeus Mujer and led by Dr. Mª Angela Pascual, was run in collaboration with researchers from the Clinical University of Navarra (Pamplona) and the University of Cagliari (Italy) and was published in the scientific review Obstetrics and Gynecology published by the American College of Obstetricians and Gynecologists.

During the follow-up period, only 130 women (31.8% of the total) underwent surgery to remove the tumour. Surgery is recommended when the ovarian teratoma causes pelvic or abdominal pain (acute or chronic), when it increases in size (by 10 mm or more) during the first two follow-up ultrasound checks (e.g. 3 to 6 months after diagnosis) or changes that could be indicative of a malignant tumour are detected, such as the appearance of solid vascularised areas.

Article de référence :
Long-term Results for Expectant Management of Ultrasonographically Diagnosed Benign Ovarian Teratomas
Pascual, M. Angela MD, PhD; Graupera, Betlem MD, PhD; Pedrero, Cristina MD; Rodriguez, Ignacio BSc; Ajossa, Silvia MD; Guerriero, Stefano MD, PhD; Alcázar, Juan Luis MD, PhD.
Obstetrics & Gynecology: December 2017 - Volume 130 - Issue 6 - p 1244–1250 doi: 10.1097/AOG.0000000000002327

Request more information

(+34) 93 227 48 96

Or fill in this form and we will call you as soon as possible

I want to be informed about the latest news of Dexeus Mujer and receive the newsletter:
If you require more information, please contact our International Patient Care Unit.